J&J Launches Volt Wrist And Proximal Humerus Plating Systems In US

Published on 06/19/2025 at 12:16

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Johnson & Johnson

Earnings, inflation data confront resilient US stocks rally	Jul. 13	RE
S&P 500 ends down as tariffs sour sentiment	Jul. 11	RE
FDA May Fast Track Drug Reviews for Lower US Prices	Jul. 11	MT
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	Jul. 11	MT
HSBC Adjusts Johnson & Johnson's Price Target to $180 From $184, Keeps Buy Rating	Jul. 11	MT
Wall St Week Ahead-Earnings, inflation data confront resilient US stocks rally	Jul. 11	RE
Morgan Stanley Adjusts PT on Johnson & Johnson to $171 From $169, Maintains Equalweight Rating	Jul. 10	MT
Jabil Inc. : Investing to stay ahead	Jul. 10
Major deals involving U.S. drugmakers and biotechs over the past decade	Jul. 09	RE
Transgene SA Announces Board Changes	Jul. 09	CI
Johnson & Johnson's Q2 Earnings Call Likely to Focus on Guidance, Tariff Impact, BofA Says	Jul. 09	MT
Company earnings: key dates for next week	Jul. 09
Trump says pharmaceutical tariffs could reach 200%	Jul. 08	RE
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	Jul. 08	MT
Pharma Stocks Pare Gains After Trump Reportedly Threatens 200% Tariff on Imported Drugs	Jul. 08	MT
Sector Update: Health Care Stocks Steady Premarket Tuesday	Jul. 08	MT
Volatility as a Strategy	Jul. 08
J&J: seeks FDA approval for Caplyta for schizophrenia	Jul. 08
Johnson & Johnson Announces the Submission of A Supplemental New Drug Application to the U.S. Food and Drug Administration Based Upon Long-Term Data Evaluating the Safety and Efficacy of Caplyta (Lumateperone) for the Prevention of Relapse in Schizophrenia	Jul. 08	CI
Johnson & Johnson Submits Supplemental NDA for Schizophrenia Treatment Caplyta	Jul. 08	MT
Nanobiotix: NBTXR3 device reclassified as a drug	Jul. 08
Nanobiotix Reports Regulatory Harmonization, New Composition of Matter Patent Filed for JNJ-1900	Jul. 07	MT
Johnson & Johnson Unit Submits EMA Application to Extend Indication of Akeega for Prostate Cancer	Jul. 03	MT
J&J Unit Seeks Indication Extension for Cancer Drug Combo in EU	Jul. 03	MT
US FDA approves Regeneron's blood cancer therapy	Jul. 02	RE